Fibrosis startup touts mid-stage NASH trial as it moves sole candidate forward
A Peter Thiel-backed biotech is reporting a positive trial in NASH — but it’s not planning on working there for the time being.
Chemomab Therapeutics, originally founded in Tel Aviv with employees based in both Israel and the US, announced Tuesday morning that its lead and only program CM-101 met the primary safety and tolerability endpoint in a Phase IIa study. Secondary endpoints were also met, including levels of validated liver fibrosis biomarkers measured at baseline and at week 20.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.